Last reviewed · How we verify
ACI-24.060 at Dose D — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
ACI-24.060 at Dose D (ACI-24.060 at Dose D) — AC Immune SA.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ACI-24.060 at Dose D TARGET | ACI-24.060 at Dose D | AC Immune SA | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ACI-24.060 at Dose D CI watch — RSS
- ACI-24.060 at Dose D CI watch — Atom
- ACI-24.060 at Dose D CI watch — JSON
- ACI-24.060 at Dose D alone — RSS
Cite this brief
Drug Landscape (2026). ACI-24.060 at Dose D — Competitive Intelligence Brief. https://druglandscape.com/ci/aci-24-060-at-dose-d. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab